SIGLEC21P

Across TCGA pan-cancer cohorts, SIGLEC21P RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated SIGLEC21P data layer.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SIGLEC21P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC21P expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

UCEC, STAD, and TGCT are the cancer types where SIGLEC21P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	0.691	0.864	.005	66	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	36	view →
TGCT	DFS	Tertile	III,IV	0.017	0.923	.021	18	view →
BLCA	DFS	Tertile	IV	0.124	0.469	.029	18	view →
LUSC	OS	Tertile	III,IV	1.000	0.364	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIGLEC21P–UCEC (OS)

Open the UCEC breakdown →